HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology commercialization and export services. We have established a "1+2+3+4=1" service system and can supply rhodium(II) octanoate sourced from multiple well-known original manufacturers.
As a research-driven foreign trade enterprise, HiSiaddi has repeatedly proposed optimized formulations and application improvement solutions for rhodium(II) octanoate through technological cooperation with manufacturers and precise market demand insight. Below is a formulation optimization consulting case for rhodium(II) octanoate delivered by HiSiaddi.
Contact HiSiaddi customer service for more formulation optimization consulting services.
Medicel Pharma S.L of Madrid, Spain, is a mid-to-high-end European specialty API CDMO specializing in industrial production of cyclopropane intermediates and novel antibiotic raw material drugs. Rhodium(II) octanoate dimer (CAS: 73482-96-9) acts as the core catalyst for carbene cyclization reactions, with a stable annual procurement volume of 72 kg pharmaceutical-grade rhodium(II) octanoate. The enterprise previously purchased high-purity products originally manufactured by Johnson Matthey, Europe.
Faced with surging European rhodium raw material prices and extended import lead times of up to 80 days, the client initiated localized procurement of domestically mass-produced rhodium(II) octanoate from China for the first time. After feeding the first batch of 32 kg into industrial production lines, successive abnormalities emerged: the target intermediate yield dropped from 95.2% (original imported catalyst) to 82%–86%, system impurities spiked, black elemental rhodium precipitated at the reactor bottom, and catalytic activity fluctuated by over 9% across separate feeding batches of the same lot. Frequent production line shutdowns and debugging were required.
Restricted by EMA pharmaceutical registration regulations in Spain, the client’s synthetic process, temperature, solvent ratio, and catalyst feeding equivalent are filed with drug regulatory authorities and cannot be modified during production. Remedial measures were limited to two dimensions: catalyst bulk formulation improvement and warehouse-storage feeding operation specifications. The original domestic supplier only produced standard mass-production formulations with no understanding of downstream cyclization reaction working conditions and could not conduct targeted product formulation optimization. The client fully entrusted HiSiaddi with fault tracing, iterative formulation optimization, and delivery of supporting operational guidance.
HiSiaddi collected three types of samples: defective domestic products, imported reference samples, and warehouse retained samples. We collaborated with a precious metal testing laboratory to conduct full physical and chemical screening, and remotely coordinated with the client’s workshop process engineers to sort out full-process operational details, accurately pinpointing three core technical defects:
1. Irrational Synthetic Raw Materials & Formulation Causing Rhodium Dimer Decomposition During Catalysis Manufacturers adopted ordinary rhodium trichloride as the starting raw material with crude synthesis and impurity removal processes, resulting in residual inorganic chloride ions of 320 ppm in finished products (pharmacopoeia limit ≤80 ppm). Excess octanoic acid feeding left free octanoic acid residues of 750 ppm (client process upper limit ≤150 ppm). Chloride ions disrupt the binuclear coordination structure of rhodium(II) octanoate, while free octanoic acid triggers side reactions in alkaline cyclization systems. The dual effects decompose the catalyst in situ, precipitating inactive black rhodium and drastically lowering product yield.
2. Lack of Trace Antioxidant Stabilizers in Formulation Leading to Poor Storage Stability & Rapid Oxidative Deterioration Post Opening No inert stabilizers were added to the standard finished product, making the material highly sensitive to air and moisture. The client stored products at room temperature in warehouses and took partial batches from open 25kg bulk drums; remaining raw materials partially oxidized and lost catalytic activity within 3–5 days after opening, causing significant catalytic performance gaps between early and late feeding from the same drum and severe batch activity differentiation.
3. Unreasonable Powder Particle Size + Improper Client Pre-Feeding Treatment Causing Uneven Material Dissolution & Local Agglomeration Natural cooling crystallization produces products with particle sizes spanning 6–52 μm. Fine powder instantly agglomerates and deactivates upon contact with organic solvents, while large particles require prolonged dissolution time. The client retained operating habits from imported catalyst usage by directly feeding dry powder into high-temperature reactors in one batch, leading to local excessive rhodium concentration, rapid agglomeration, and rhodium black precipitation, further amplifying activity fluctuation defects.
1. Replace Rhodium Source & Optimize Feeding Ratio to Control Chloride & Free Octanoic Acid Substitute rhodium trichloride with high-purity rhodium hydroxide as the starting material to cut chloride introduction at the source. Precisely control the molar ratio of octanoic acid to rhodium, abandoning the original excess feeding scheme. Adopt two-stage low-temperature recrystallization with ethanol and cold pure water plus multi-stage washing for impurity removal, ultimately limiting finished product chloride ions ≤65 ppm and free octanoic acid within 110–140 ppm to meet client process limits.
2. Compound Food-Grade Inert Antioxidant Additives to Boost Storage Stability Trace inert carboxylic acid stabilizers are added to finished products without interfering with cyclization catalytic activity. Vacuum low-temperature drying is applied to final products, achieving activity attenuation <2.5% after 6 months of sealed storage at room temperature and resolving rapid deterioration after open storage.
3. Optimize Crystal Growth Formulation for Narrow Particle Size Distribution During recrystallization, implement uniform cooling at a slow rate of 0.6°C/h and add trace food-grade seed crystals to regulate crystal growth, stabilizing D50 within the 19–24 μm narrow range. Uniform powder dissolution rate eliminates dissolution time differences between coarse and fine particles.
HiSiaddi sent three rounds of improved samples to the client’s Spanish laboratory for small-scale trials, fine-tuning formulation details based on cyclization yield data before finalizing the mass-production formulation.
1. Optimize Pre-Feeding Pretreatment Process Eliminate direct dry powder feeding. Pre-disperse the catalyst in deoxygenated anhydrous toluene at a low temperature of 12°C in a sealed environment for 30 minutes, filter out surface oxidized deteriorated fine powder before transferring to the reactor to prevent degraded materials from generating rhodium black inside the vessel.
2. Split Packaging Specifications & Adjust Warehouse Storage Conditions Replace 25kg bulk drums with 1kg argon-sealed vacuum aluminum foil small packages for single-use after opening. Store raw materials in light-proof refrigeration at 2–8°C to isolate water vapor and air oxidation.
3. Adjust Feeding Rhythm Change one-time full feeding to two split additions with a 40-minute interval to reduce instantaneous local rhodium concentration and lower agglomeration-induced deactivation risks.
1. Medium-Scale Trial Acceptance Met Standards The manufacturer mass-produced 40kg materials per the revised formulation, accompanied by bilingual Chinese-English COA complying with USP and Spanish pharmacopoeia standards plus SVHC screening reports. After delivery to the client’s facility, full-line medium-scale production delivered stable cyclopropane intermediate yields of 94.7%–95.3%, matching original imported catalysts. Rhodium black residue at reactor bottoms reduced by over 90%, and batch activity fluctuations were controlled within ±1.2%, restoring full-load continuous production capacity for the workshop.
2. Annual Order Executed The remaining 32 kg is shipped in 4 batches monthly, and a formal 72kg annual procurement framework was signed. Localized procurement costs decreased by 31.5% versus original imports, and sea freight lead times were shortened from 80 days to 23 days.
3. Business Expansion The client launched medium-scale trials for a new generation of anti-infective drugs the following year requiring low-moisture modified rhodium(II) octanoate grades and again entrusted HiSiaddi with overall formulation customization. The Spanish pharmaceutical enterprise also referred two other high-end European CDMOs from Portugal and Italy to trial and purchase materials from HiSiaddi.
Most domestic rhodium(II) octanoate manufacturers focus on mass production cost control with fixed long-term formulations and lack downstream cyclization process application data from European and American pharmaceutical manufacturers, making targeted formulation adjustments impossible in response to terminal production abnormalities. Mid-to-high-end European pharmaceutical enterprises face fixed registered mass production processes constrained by drug regulatory laws; minor catalyst formulation defects can trigger sharp drops in full-line yield. Leveraging professional reserves in precious metal catalysis, HiSiaddi built a full technical service chain covering fault diagnosis, refined formulation improvement, client feeding specification optimization, and mass production quality control delivery. We resolved information barriers between supply and demand through technical expertise and secured sustained repeat orders from high-end overseas clients.
Contact HiSiaddi customer service for more formulation optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
